Business Context and Reporting Period
This Form 8-K filing by Avalo Therapeutics, Inc. (AVTX) is dated July 22, 2022. The report addresses the company's compliance status with the Nasdaq Capital Market regarding the minimum bid price requirement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
The primary event reported is the resolution of a listing deficiency:
- Prior Status: On March 17, 2022, Nasdaq notified the Company that its common stock had closed below the $1.00 minimum bid price requirement for 30 consecutive business days.
- Resolution: On July 22, 2022, Nasdaq confirmed the Company regained compliance after maintaining a closing price of $1.00 or greater for ten consecutive trading days (July 8 to July 21, 2022).
- Outcome: The matter regarding the Bid Price Rule is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of future risks beyond the resolution of the specific listing deficiency. No unusual items or contingencies are disclosed in this report.
Investor Verification Checklist
- Verify the current trading price of AVTX to ensure continued compliance with Nasdaq listing rules.
- Review the company's most recent 10-Q or 10-K filings for actual financial performance and liquidity status, as this 8-K does not provide such data.
- Confirm that no other Nasdaq deficiency notices are currently outstanding.